The medical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s showing significant potential in clinical trials for addressing obesity. Unlike some available weight loss approaches, retatrutide appears to deliver a greater substantial reduction in body mass and benefit metabolic markers, par